|
Software for prediction of NDSRI generation
|
|
5
|
913
|
October 24, 2024
|
|
Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide impurity formation and its inhibition in bumetanide tablets -Pub
|
|
7
|
1365
|
October 19, 2024
|
|
Nitrosamine mitigation: NDMA impurity formation and its inhibition in metformin hydrochloride tablets -Pub FDA
|
|
2
|
280
|
October 15, 2024
|
|
Reactivities of N-Nitrosamines against Common Reagents and Reaction Conditions -Pub
|
|
2
|
458
|
October 15, 2024
|
|
Selection of Solvent and Positive Control Concentration for Enhanced Ames Test Conditions for N-Nitrosamine Compounds -Pub
|
|
0
|
205
|
October 11, 2024
|
|
N-Nitrosamines: bacterial mutagenesis and in vitro metabolism -A MUST READ
|
|
9
|
1034
|
October 10, 2024
|
|
Dynamics of Nitroso-STG-19 entering the blood circulation
|
|
1
|
151
|
October 10, 2024
|
|
Aptar’s N-Sorb Nitrosamine Mitigation Solution Accepted to US FDA’s Emerging Technology Program
|
|
6
|
679
|
October 2, 2024
|
|
New paper - Use of molar, instead of weight-based, safety limits
|
|
17
|
3198
|
September 25, 2024
|
|
🙋♂️ Citizen Petition to FDA on Sitagliptin
|
|
21
|
3774
|
June 7, 2024
|
|
Escaping the cohort of concern: in vitro experimental evidence supports non-mutagenicity of N-nitroso-hydrochlorothiazide -Pub
|
|
1
|
301
|
September 18, 2024
|
|
Can API with amide should considered a potential candidate for forming nitrosamine impurity
|
|
5
|
840
|
September 12, 2024
|
|
Synthesis and mutagenic risk of avanafil's potential genotoxic impurities -Pub
|
|
0
|
207
|
August 25, 2024
|
|
Gut Microbiotica Carcinogen Metabolism - Nitrosamines
|
|
5
|
258
|
August 7, 2024
|
|
Strategy to Assess and Control Nitrosamine Formation in API during Storage: A Sitagliptin Case Study
|
|
0
|
531
|
August 6, 2024
|
|
N-nitroso Tamsulosin identification in Tamsulosin Products by LC-MS/MS
|
|
0
|
349
|
August 1, 2024
|
|
Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study -Pub
|
|
1
|
428
|
July 31, 2024
|
|
Kinetic Model for Assessing Potential Nitrosamine Carcinogenicity
|
|
1
|
207
|
July 30, 2024
|
|
Nitrosamine Contamination of Pharmaceuticals: Cases in Japan, Formation Mechanisms, Detection Methods, Regulatory Perspectives, and Insights -Pub
|
|
1
|
227
|
July 30, 2024
|
|
How to overcome the challenges of manual read-across when assessing nitrosamine acceptable intake limits
|
|
0
|
158
|
July 26, 2024
|
|
Leveraging ICH M7 Control Options 3 and 4: Discussion and Clarification Using Industrial Case Studies -Pub
|
|
0
|
708
|
July 23, 2024
|
|
Quantum Mechanical Assessment of Nitrosamine Potency -Pub
|
|
3
|
595
|
July 15, 2024
|
|
AZIDO Impurities Topic
|
|
4
|
1465
|
July 11, 2024
|
|
A Case to Support the Continued Use of Rifampin in Clinical Drug–Drug Interaction Studies -Pub
|
|
0
|
196
|
July 10, 2024
|
|
Non-mutagenic, carcinogenic impurities
|
|
3
|
850
|
June 30, 2024
|
|
Discussion on Cleaning Validation Requirements for Nitrosamines
|
|
3
|
1180
|
June 24, 2024
|
|
On the role of digital tools in nitrosamine risk assessment for drug substance and drug product manufacturing processes -Pub
|
|
0
|
248
|
June 13, 2024
|
|
EMA-funded project to predict in-vivo mutagenicity / mutagenicity classification
|
|
9
|
1258
|
June 11, 2024
|
|
A new root cause? NOx
|
|
13
|
2453
|
November 17, 2023
|
|
Formaldehyde Catalysis of Nitrosamine Formation
|
|
3
|
757
|
May 31, 2024
|